Drugs / Glucovance
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | GLUCOVANCE | — | 2000-07-31 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00035542 | Dec 2001 → Oct 2003 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT02726490 Comparator | Jul 2016 → Aug 2018 | gestational diabetes | Texas Tech University Health Sciences Center, El Paso | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glucovance | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02726490 ↗ |
| Known as | metformin HCl/glyburide | “Glucovance (metformin HCl/glyburide)” NCT00035542 ↗ |
| Route | Oral | “taken orally (PO)” NCT02726490 ↗ |